ORIGINAL ARTICLE

Comparison of Protein-C levels in diabetes melitus type 2 patients with and without ulcers at Haji Adam Malik Hospital Medan Indonesia May-July 2017

Zulfahmi Zulfa, Andri I Mardia, Savita Handayani, Santi Syafril, Dairion Gatot

Zulfahmi Zulfa
Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Andri I Mardia
Universitas Sumatera Utara, Medan, Indonesia

Savita Handayani
Universitas Sumatera Utara, Medan, Indonesia

Santi Syafril
Universitas of Sumatera Utara, Medan, Indonesia

Dairion Gatot
Universitas Sumatera Utara, Medan, Indonesia. Email: dairion.gatot@usu.ac.id
Online First: December 01, 2019 | Cite this Article
Zulfa, Z., Mardia, A., Handayani, S., Syafril, S., Gatot, D. 2019. Comparison of Protein-C levels in diabetes melitus type 2 patients with and without ulcers at Haji Adam Malik Hospital Medan Indonesia May-July 2017. Bali Medical Journal 8(3): 790-794. DOI:10.15562/bmj.v%vi%i.913


Introduction People with diabetes mellitus (DM) have an increased risk for thrombosis compared with non-diabetic patients. Several studies showed contradicting in data on levels of protein C in people with type 2 DM and diabetic ulcers.

Methods This is a descriptive and analytical cross-sectional study on protein C concentration of patients with type 2 DM with and without foot ulcers. The control group was the type 2 DM patients without foot ulcers, whereas the case group was the type 2 DM patients with a rigid diabetic foot ulcer based on the Wagner criteria. Blood samples are then taken after 8 to 10 hours of fasting to check for protein C concentration and hemostasis examination including platelet count, prothrombin time (PT),  activated partial thromboplastin time (aPTT), thrombin time (TT), fibrinogen levels, and D-dimers.

Results Of a total of 20 samples, there was no statistically significant difference in protein C levels of diabetic foot ulcers with hypercoagulation compared with no diabetic foot ulcers with hypocoagulation and no significant correlation between grade diabetic foot ulcers and protein C concentration.

References

Suharti C. Dasar Dasar Hemostasis. In: Setiati, S, Alwi I, Sudoyo A, Simadibrata K, Setyohadi B, Syam AF (editor). Buku Ajar Ilmu Penyakit Dalam. Ed ke-6. Interna publishing, Jakarta. 2014; pg. 2751-9

Oesman F, Setiabudy RD. Fisiologi Hemostasis dan Fibrinolisis. In: Setiabudy RD (editor). Hemostasis dan Trombosis. Ed ke-3. Balai penerbit FKUI, Jakarta; 2007.

Setiabudy RD. Patofisiologi Trombosis. In: Setiabudy RD (editor). Hemostasis dan thrombosis. Ed ke-3. Balai penerbit FKUI; Jakarta: 2007.

Carr ME. Diabetes mellitus. Journal of Diabetes and its Complications, 2001. 15(1), pp. 44–54.

Benyamin AF, Gustaviani R, Gangguan Hemostasis Pada Diabetes Melitus. Didalam: Setiati S, Alwi I, Sudoyo A, Simadibrata K, Setyohadi B, Syam AF (editor). Buku Ajar Ilmu Penyakit Dalam. Ed ke- 6. Interna publishing, Jakarta, 2014.

Santoso M. et al. Pattern of Diabetic Foot at Koja Regional General Hospital. Acta Medica Indonesiana , 2005. 37(4), pp.187-189.

Tseng CH. Prevalence and Risk Factors of Diabetic Foot Problems in Taiwan: A cross-sectional survey of non-type 1 diabetic patients from a nationally representative sample. Diabetes Care, 2003. 26(12), pp.3351–3351.

Kalani M, et al. Effect of Dalteparin on Healing of Chronic Foot Ulcers in Patients With Peripheral Arterial Occlusive Disease: A prospective, randomized, double-blind, placebo-controlled study. Diabetes Care, 2003. 26(9), pp.2575–2580.

Kalani M, et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thrombosis Research, 2007. 120(5), pp.653–661.

Bolaman Z. et al. The Changes of Coagulation Parameters and Microvascular Complications in Diabetes Mellitus. The Endocrinologist, 2007. 17(4), pp.196–199.

Madan R. et al. Coagulation Profile in Diabetes and its Association with Diabetic Microvascular Complications. J Assoc Physicians India, 2010. 58, pp.481–484.

Yan SB, et al. Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis. Chest, 2001. 120(3), pp.915–922.

Whitmont, K. et al. Low Circulating Protein C Levels Are Associated with Lower Leg Ulcers in Patients with Diabetes. BioMed Research International, 2013, pp.1–4.

Yekta Z. Pourali & Ghasemi-Rad M. Comparison of demographic and clinical characteristics influencing health-related quality of life in patients with diabetic foot ulcers and those without foot ulcers. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, p.393

Al-Rubeaan K. et al. Diabetic Foot Complications and Their Risk Factors from a Large Retrospective Cohort Study. Plos One, 10(5). 2015.

Gunes EA. et al. Relation with mean platelet volume and diabetic foot ulcers. Acta Medica Mediterranea, 2017.

Wright JA, Oddy MJ, Richards T. Presence and Characterisation of Anaemia in Diabetic Foot Ulceration. Anemia, 2014, pp.1–8.

Salman IN, Wadod, SA, Abualkasem BA. Low Hemoglobin Levels in Infected Diabetic Foot Ulcer. Journal of Pharmacy and Biological Sciences, 2017. 12(01), pp.05-09

Li XH, et al. Fibrinogen: A Marker in Predicting Diabetic Foot Ulcer Severity. Journal of Diabetes Research, 2016, pp.1–5.

Suhartono, Gatot D. Hiperkoagulasi pada penderita ulkus kaki diabetika. [TESIS]. Medan: Departemen Ilmu Penyakit Dalam. 2008.

Dahlback B. Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure-Function Relationships and Molecular Recognition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005. 25(7), pp.1311–20.

Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood, 2007. 109(8), pp.3161–3172.

Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost. 1997. 78, pp.427– 433.

Rezaie A. Regulation of the Protein C Anticoagulant and Antiinflammatory Pathways. Current Medicinal Chemistry, 2010. 17(19), pp.2059–69.

Bouwens EAM, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective action of the protein C pathway. Journal of Thrombosis and Haemostasis, 2013. 11, pp.242–253.

Yano Y. et al. Association Between Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels and Activated Protein C in Normotensive Type 2 Diabetic Patients. Diabetes Care, 2002. 25(7), pp.1245–1246.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0